GeneDx Announces Completion of Fabric Genomics Acquisition
'Healthcare is at an inflection point where genomic insights must be integrated into standard care to improve outcomes and reduce costs,' said Katherine Stueland, President and CEO of GeneDx. 'With Fabric Genomics now part of GeneDx, we're uniquely positioned to deliver earlier and more accurate diagnoses worldwide, from NICUs and pioneering newborn screening programs to health systems across the globe.'
The combination of GeneDx's industry leading exome and genome testing and unmatched rare disease data asset with Fabric Genomics' advanced AI interpretation services establishes a new ecosystem for genomic diagnostics. The integrated model offers greater flexibility for providers and health systems, enabling seamless workflow integration for both centralized and decentralized genomic services, all powered by GeneDx's deep clinical expertise and Fabric's advanced interpretation technology.
Fabric Genomics will operate independently as a subsidiary of GeneDx, continuing to drive momentum with commercial support from GeneDx. The acquisition accelerates several key growth opportunities for GeneDx:
NICU Genomic Testing: Accelerates time-to-diagnosis for critically ill newborns with scalable genomic solutions that integrate into major health system workflows, enabling GeneDx to deliver flexible end-to-end offerings and increase access to testing.
Genomic Newborn Screening (gNBS): Positions GeneDx to support large-scale newborn screening programs in the U.S. and globally.
Global Commercial Expansion: Enables flexible, regulation-compliant models for AI-powered interpretation services across EMEA, APAC, LATAM, and more.
Platform Economics: Unlocks recurring software-based revenue streams through Fabric's interpretation-as-a-service model.
Advisors:
Fenwick & West LLP served as legal advisor to GeneDx.
TD Cowen served as exclusive financial advisor to Fabric Genomics in connection with the acquisition while DLA Piper LLP (US) served as legal advisor to Fabric Genomics.
About GeneDx:
At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.
About Fabric Genomics:
Fabric Genomics, a wholly owned subsidiary of GeneDx, is transforming healthcare through its AI-driven interpretation of the human genome. The company provides organizations with end-to-end clinical sequence analysis solutions that include the Fabric Enterprise software platform and expert clinical interpretation services needed to scale genetic testing. At the core of our platform is a suite of sophisticated AI algorithms and data knowledge systems that turn genomic data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women's health. To learn more, visit fabricgenomics.com and follow us on X (Twitter) and LinkedIn.
Forward Looking Statements
This press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Grocery Outlet (GO) Q2 Earnings: What To Expect
Discount grocery store chain Grocery Outlet (NASDAQ:GO) will be reporting results this Tuesday after the bell. Here's what investors should know. Grocery Outlet met analysts' revenue expectations last quarter, reporting revenues of $1.13 billion, up 8.5% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Grocery Outlet a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Grocery Outlet's revenue to grow 5.2% year on year to $1.19 billion, slowing from the 11.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.17 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Grocery Outlet has missed Wall Street's revenue estimates twice over the last two years. Looking at Grocery Outlet's peers in the non-discretionary retail segment, only Sprouts has reported results so far. It beat analysts' revenue estimates by 2.3%, delivering year-on-year sales growth of 17.3%. The stock was down 4.1% on the results. Read our full analysis of Sprouts's earnings results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the non-discretionary retail stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.1% on average over the last month. Grocery Outlet is up 4.2% during the same time and is heading into earnings with an average analyst price target of $15.62 (compared to the current share price of $13.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
13 minutes ago
- Yahoo
Flywire (FLYW) To Report Earnings Tomorrow: Here Is What To Expect
Cross border payment processor Flywire (NASDAQ: FLYW) will be announcing earnings results this Tuesday after the bell. Here's what to look for. Flywire beat analysts' revenue expectations by 5% last quarter, reporting revenues of $133.5 million, up 17% year on year. It was a strong quarter for the company, with a solid beat of analysts' EBITDA estimates. Is Flywire a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Flywire's revenue to grow 20.9% year on year to $125.4 million, slowing from the 22.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.07 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Flywire has missed Wall Street's revenue estimates three times over the last two years. Looking at Flywire's peers in the finance and hr software segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Workiva delivered year-on-year revenue growth of 21.2%, beating analysts' expectations by 3%, and Asure reported revenues up 7.4%, falling short of estimates by 3.2%. Workiva traded up 32.2% following the results while Asure was down 13.6%. Read our full analysis of Workiva's results here and Asure's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the finance and hr software stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 5% on average over the last month. Flywire is down 11.3% during the same time and is heading into earnings with an average analyst price target of $13.45 (compared to the current share price of $10.57). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
J&J Snack Foods (JJSF) Reports Earnings Tomorrow: What To Expect
Snack food company J&J Snack Foods (NASDAQ:JJSF) will be reporting earnings this Tuesday morning. Here's what investors should know. J&J Snack Foods missed analysts' revenue expectations by 3.2% last quarter, reporting revenues of $356.1 million, down 1% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' adjusted operating income estimates and a significant miss of analysts' EBITDA estimates. Is J&J Snack Foods a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting J&J Snack Foods's revenue to grow 1.2% year on year to $445.3 million, slowing from the 3.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.76 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. J&J Snack Foods has missed Wall Street's revenue estimates five times over the last two years. Looking at J&J Snack Foods's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hershey delivered year-on-year revenue growth of 26%, beating analysts' expectations by 3.1%, and Lamb Weston reported revenues up 4%, topping estimates by 5.7%. Hershey's stock price was unchanged after the resultswhile Lamb Weston was up 19.3%. Read our full analysis of Hershey's results here and Lamb Weston's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the shelf-stable food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.4% on average over the last month. J&J Snack Foods is down 3.6% during the same time and is heading into earnings with an average analyst price target of $144 (compared to the current share price of $112.21). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. 登入存取你的投資組合
